文献速递神经免疫神经重症与神经感染

SARS-CoV-2感染后自身免疫性脑炎:病例频率、表现与结局

Autoimmune Encephalitis After SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes.
PubMed 文献 · Neurology · 2021-10-11

本研究基于Mayo Clinic Rochester的556例连续自身免疫性脑病抗体检测残留血清及31例COVID-19相关脑病会诊队列,发现 laboratory cohort中3% SARS-CoV-2抗体阳性,其中2例诊断AE;脑病队列中5例(16%)符合AE诊断标准,占2020年该中心10384例COVID-19患者的0.05%。5例AE患者神经抗体均阴性,临床表现多样,3例可能AE自行缓解,1例 definite limbic encephalitis免疫治疗有效但残留情绪记忆问题,1例probable rhombencephalitis免疫治疗无效死亡。

要点

  • COVID-19后AE罕见,占2020年该中心COVID-19患者的0.05%。
  • AE患者神经IgG及脑脊液病毒检测均阴性,临床表现多样。
  • 诊断标准有助于区分AE与系统性感染中的中毒代谢性脑病。

核心结论

  • COVID-19大流行期间偶见AE病例,临床表现多样,神经IgG和脑脊液病毒颗粒阴性。
  • 应用诊断标准有助于将AE与系统性感染背景下的中毒代谢性原因区分开。

研究设计与样本

  • 脑病队列:31例神经内科COVID-19相关会诊患者,与实验室队列交叉参照。

主要发现

  • 脑病队列中5例(16%)符合AE诊断标准,占2020年Mayo Clinic Rochester 10384例COVID-19患者的0.05%。
  • 5例AE患者中 definite 1例、probable 1例、possible 3例;中位起病年龄61岁(范围46-63),女性3例。
  • 5例神经IgG均阴性,4例检测脑脊液SARS-CoV-2 PCR/IgG指数均为阴性。
  • 表现包括谵妄5例、癫痫发作2例、菱脑炎1例、失语1例、共济失调1例;3例possible AE自行缓解,1例definite边缘叶脑炎免疫治疗有效但残留情绪和记忆问题,1例probable自身免疫性菱脑炎免疫治疗无效死亡。

关键数值与推荐

  • AE诊断标准:definite 1例、probable 1例、possible 3例。
  • 脑病队列AE比例16%(5/31),占全部COVID-19患者的0.05%(5/10384)。

临床怎么用

  • 在COVID-19相关脑病患者中,若表现多样且神经抗体阴性,仍需考虑AE可能。
  • 应用AE诊断标准有助于与中毒代谢性脑病鉴别。
  • 部分AE患者可自行缓解,但重症如菱脑炎可能免疫治疗无效死亡。

局限性

  • 实验室队列为残留血清回顾性检测,部分患者资料不可用(2例)。
  • 脑病队列样本量小(n=31),AE病例数少(n=5)。
  • 仅4例检测了脑脊液SARS-CoV-2 PCR/IgG指数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Autoimmune encephalitis (AE) cases after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported, but the frequency is unknown. We aimed to determine the frequency and diagnostic features of coronavirus disease 2019 (COVID-19)-related AE. METHODS: Residual sera from 556 consecutive Mayo Clinic Rochester patients (laboratory cohort) who underwent autoimmune encephalopathy neural immunoglobulin G (IgG) evaluation were tested for total antibodies against the SARS-CoV-2 spike glycoprotein using a Food and Drug Administration-authorized chemiluminescence assay (October 2019-December 2020). Clinical records from patients with a positive SARS-CoV-2 antibody result and available research consent were reviewed. This laboratory cohort was cross-referenced with the Department of Neurology's COVID-19-related consultative experience (encephalopathy cohort, n = 31). RESULTS: Eighteen of the laboratory cohort (3%) were SARS-CoV-2 antibody positive (April-December 2020). Diagnoses were as follows: AE, 2; postacute sequelae of SARS CoV-2 infection (PASC), 3; toxic-metabolic encephalopathy during COVID-19 pneumonia, 2; diverse non-COVID-19 relatable neurologic diagnoses, 9; unavailable, 2. Five of the encephalopathy cohort had AE (16%, including the 2 laboratory cohort cases that overlapped), representing 0.05% of 10,384 patients diagnosed and cared for with any COVID-19 illness at Mayo Clinic Rochester in 2020. The 5 patients met definite (n = 1), probable (n = 1), or possible (n = 3) AE diagnostic criteria; median symptom onset age was 61 years (range, 46-63); 3 were women. All 5 were neural IgG negative and 4 tested were SARS-CoV-2 PCR/IgG index negative in CSF. Phenotypes (and accompanying MRI and EEG findings) were diverse (delirium [n = 5], seizures [n = 2], rhombencephalitis [n = 1], aphasia [n = 1], and ataxia [n = 1]). No acute disseminated encephalomyelitis cases were encountered. The 3 patients with possible AE had spontaneously resolving syndromes. One with definite limbic encephalitis was immune therapy responsive but had residual mood and memory problems. One patient with probable autoimmune rhombencephalitis died despite immune therapy. The remaining 26 encephalopathy cohort patients had toxic-metabolic diagnoses. DISCUSSION: We encountered occasional cases of AE in our 2020 COVID-19 experience. Consistent with sporadic reports and small case series during the COVID-19 pandemic, and prior experience of postinfectious AE, our cases had diverse clinical presentations and were neural IgG and CSF viral particle negative. Application of diagnostic criteria assists in differentiation of AE from toxic-metabolic causes arising in the setting of systemic infection.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Valencia Sanchez C, Theel E, Binnicker M, et al. Autoimmune Encephalitis After SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes. Neurology. 2021. PMID: 34635560. doi:10.1212/WNL.0000000000012931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。